Long title
A Phase 3, Randomized, Double-blind, Placebo-controlled study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1 + Synovial Sarcoma Subjects Following First-line Systemic Anti-cancer Therapy
Date receipt dossier
EudraCT number
2018-000824-32
Company / Sponsor
Immune Design
Phase
III
Treated organism
Humans
Indication category
Cancer therapy
Disease
Synovial sarcomas
Therapeutic approach
Immunotherapy
Genetic modification
Replication deficient lentiviral vector encoding NY-ESO-1 cancer testis antigen
Method of transfer of nucleic acid of interest
not applicable
Administered biological material
Recombinant replication defective lentiviral vector (LV305)
Route of administration
Subcutaneous
Locations in Belgium
UZ Leuven
Type of procedure
Contained use only
Current status
Under evaluation